Research peptide companies selling BPC-157, TB-500, PT-141, and similar compounds face real liability exposure — even when products are labeled 'not for human use.' Here's what the right coverage looks like.
PRIA Brokers
PRIA Brokers — Peptide Insurance Specialist
One of the most persistent misconceptions in the research peptide market is that labeling products "for research use only" or "not for human use" provides meaningful legal protection against product liability claims.
It does not.
If your BPC-157, TB-500, Selank, Epithalon, or other research peptide ends up being used by a human — which is essentially universal in the research peptide market — and that person suffers harm they attribute to your product, you will be named in any resulting claim. Courts have repeatedly held that research-use disclaimers do not insulate manufacturers and distributors from product liability when they know or should know their products are being used by humans.
Research peptide companies face a distinctive combination of risks:
Your product causes or allegedly causes harm to a user. This is the most fundamental exposure and the one most likely to result in litigation. Claims can allege manufacturing defects (contamination, incorrect purity), design defects (inherent risks of the compound), or warning defects (inadequate disclosure of risks).
The FDA has increased scrutiny of companies marketing peptides that are used by humans but labeled as research chemicals. Warning letters targeting BPC-157 and other compounds have been issued. FTC scrutiny of health claims is active. State attorneys general are pursuing consumer protection actions against companies they believe are skirting drug regulations through research-use labeling.
If your company provides technical guidance — dosing protocols, formulation recommendations, stacking advice — you are providing professional services. If that advice leads to a user harm, E&O coverage responds.
Many research peptides are sourced from overseas manufacturers. If the underlying API is contaminated, mislabeled, or subpotent, and you distributed it, you face liability even if the problem originated with your supplier.
One of the most widely distributed research peptides. Used extensively for tissue repair and anti-inflammatory effects. Adverse event reports are relatively limited, but regulatory attention has increased. Product liability coverage essential.
Popular in athletic recovery applications. High human use despite research-only labeling. Supply chain quality variability creates product liability exposure.
An FDA-approved drug (Vyleesi) that also circulates as a research peptide. Companies selling PT-141 as a research compound face significant regulatory and liability exposure given its approved drug status.
Russian nootropic peptides with limited Western regulatory history. Novel compound liability — limited adverse event data means unknowns remain.
Longevity-focused peptide with an active consumer market. Increasing use outside clinical settings creates product liability exposure.
Growth hormone secretagogues with significant human use. These compounds have attracted FDA warning letters and state enforcement actions.
A properly structured program for research peptide companies includes:
**Product Liability**
Covers bodily injury and property damage claims arising from your products. Must specifically include research peptides and not exclude products with pharmaceutical applications.
**Errors & Omissions**
Covers claims arising from technical guidance, formulation advice, and professional representations made to customers.
**Regulatory Defense**
Covers legal costs associated with FDA warning letters, FTC investigations, and state enforcement actions targeting your products or marketing claims.
**Advertising Liability**
Covers claims arising from your website, marketing materials, and product descriptions — including allegations that your research-use claims are misleading.
Standard commercial insurance markets routinely decline to insure research peptide companies — or issue policies that exclude the core risks. Specialty markets that understand the research peptide space are necessary.
PRIA Brokers has placed coverage for research peptide companies ranging from small domestic operations to large-scale distributors. We understand the specific risks of BPC-157, TB-500, and other compounds, and we work with carriers who write this risk correctly.
Contact us at (888) 998-7742 or dhamid@priabrokers.com to discuss your research peptide operation and get a coverage review.
PRIA Brokers specializes in coverage for peptide manufacturers, GLP-1 compounders, distributors, and suppliers. Compare quotes from A-rated specialty carriers.